气道压力释放通气在COVID-19所致急性呼吸衰竭患者中的应用:单中心随机对照试验结果
主要终点无呼吸机天数两组分别为3.7(0-15)和5.2(0-19),差异无统计学意义(p=0.28)。气道压力释放通气组前7天PaO2/FiO2和静态顺应性较高,但短暂严重高碳酸血症更常见(42% vs 15%,p=0.009)。总死亡率69%,两组无显著差异(78% vs 60%,p=0.07)。
要点
- 在重症COVID-19相关ARDS插管患者中,气道压力释放通气与低潮气量通气相比无呼吸机天数无显著差异(3.7 vs 5.2,p=0.28)。
- 气道压力释放通气组前7天PaO2/FiO2较高(平均差26,95%CI 13-38,p<0.001),静态顺应性较高(平均差3.7 mL/cm H2O,95%CI 0.2-7.2,p=0.03)。
- 气道压力释放通气组短暂严重高碳酸血症(Pco2≥55且pH<7.15)更常见(42% vs 15%,p=0.009)。
- 总死亡率69%,两组无显著差异(气道压力释放通气78% vs 低潮气量60%,p=0.07)。
- 气道压力释放通气组平均气道压较高(平均差3.1 cm H2O,95%CI 2.1-4.1,p<0.001),潮气量较高(平均差0.76 mL/kg预测体重,95%CI 0.5-1.0,p<0.001)。
适用人群与场景
- 成年(成人)重症COVID-19相关ARDS插管患者,来自墨西哥单中心ICU,插管48小时内随机分组。
诊断标准与关键阈值
- 原文未提及诊断标准的具体条件或评分界值。
- 短暂严重高碳酸血症定义为Pco2≥55且pH<7.15。
处置流程与药物剂量
- 插管48小时内随机接受气道压力释放通气或继续低潮气量通气;原文未提及具体呼吸机参数设置、药物剂量或撤机流程。
红旗征与不能漏的情况
- 气道压力释放通气组短暂严重高碳酸血症(Pco2≥55且pH<7.15)发生率更高(42% vs 15%,p=0.009),需监测。
研究设计与关键结果
- 主要终点无呼吸机天数:气道压力释放通气组3.7(0-15) vs 低潮气量组5.2(0-19),p=0.28。
- 前7天气道压力释放通气组PaO2/FiO2较高(平均差26,95%CI 13-38,p<0.001),静态顺应性较高(平均差3.7 mL/cm H2O,95%CI 0.2-7.2,p=0.03),平均气道压较高(平均差3.1 cm H2O,95%CI 2.1-4.1,p<0.001),潮气量较高(平均差0.76 mL/kg预测体重,95%CI 0.5-1.0,p<0.001)。
- 短暂严重高碳酸血症(Pco2≥55且pH<7.15)气道压力释放通气组42% vs 低潮气量组15%(p=0.009)。
- 总死亡率69%,气道压力释放通气组78% vs 低潮气量组60%(p=0.07);其他结局相似。
证据类型、等级与局限
- 研究类型:单中心随机对照试验。
对床旁实践的改变
- 在重症COVID-19相关ARDS插管患者中,气道压力释放通气未显示无呼吸机天数或死亡率获益,不应常规用于改善这些结局。
- 使用气道压力释放通气时需警惕短暂严重高碳酸血症(Pco2≥55且pH<7.15)发生率较高。
- 原文未提及适用或不适用人群的进一步建议。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Airway pressure release ventilation is a ventilatory mode characterized by a mandatory inverse inspiratory:expiratory ratio with a very short expiratory phase, aimed to avoid derecruitment and allow spontaneous breathing. Recent basic and clinical evidence suggests that this mode could be associated with improved outcomes in patients with acute respiratory distress syndrome. The aim of this study was to compare the outcomes between airway pressure release ventilation and traditional ventilation targeting low tidal volume, in patients with severe coronavirus disease 2019.
DESIGN: Single-center randomized controlled trial.
SETTING: ICU of a Mexican referral center dedicated to care of patients with confirmed diagnosis of coronavirus disease 2019.
PATIENTS: Ninety adult intubated patients with acute respiratory distress syndrome associated with severe coronavirus disease 2019.
INTERVENTIONS: Within 48 hours after intubation, patients were randomized to either receive ventilatory management with airway pressure release ventilation or continue low tidal volume ventilation.
MEASUREMENTS AND MAIN RESULTS: Forty-five patients in airway pressure release ventilation group and 45 in the low tidal volume group were included. Ventilator-free days were 3.7 (0-15) and 5.2 (0-19) in the airway pressure release ventilation and low tidal volume groups, respectively (p = 0.28). During the first 7 days, patients in airway pressure release ventilation had a higher Pao2/Fio2 (mean difference, 26 [95%CI, 13-38]; p < 0.001) and static compliance (mean difference, 3.7 mL/cm H2O [95% CI, 0.2-7.2]; p = 0.03), higher mean airway pressure (mean difference, 3.1 cm H2O [95% CI, 2.1-4.1]; p < 0.001), and higher tidal volume (mean difference, 0.76 mL/kg/predicted body weight [95% CI, 0.5-1.0]; p < 0.001). More patients in airway pressure release ventilation had transient severe hypercapnia, defined as an elevation of Pco2 at greater than or equal to 55 along with a pH less than 7.15 (42% vs 15%; p = 0.009); other outcomes were similar. Overall mortality was 69%, with no difference between the groups (78% in airway pressure release ventilation vs 60% in low tidal volume; p = 0.07).
CONCLUSIONS: In conclusion, when compared with low tidal volume, airway pressure release ventilation was not associated with more ventilator-free days or improvement in other relevant outcomes in patients with severe coronavirus disease 2019.
参考来源
- Ibarra-Estrada MÁ, García-Salas Y, Mireles-Cabodevila E, et al. Use of Airway Pressure Release Ventilation in Patients With Acute Respiratory Failure Due to COVID-19: Results of a Single-Center Randomized Controlled Trial. Crit Care Med. 2022. PMID: 34593706. doi:10.1097/CCM.0000000000005312
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。